Search
TG Therapeutics Inc
TGTXAdd to Watchlist
54.860USD
-0.890-1.60%
Close 07-28 16:00（ET）Quotes delayed by 15 min
8.40BMarket Cap
17.14P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-27The current earnings forecast score of TG Therapeutics Inc is 7.56, ranking 100 out of 155 in the Pharmaceuticals industry. The average price target is 49.00, with a high of 60.00 and a low of 13.00.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
67.833
Target Price
+21.04%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
TG Therapeutics Inc
TGTX
8
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
34
Pfizer Inc
PFE
32
AbbVie Inc
ABBV
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is TG Therapeutics Inc's expected revenue for the next quarter?
TG Therapeutics Inc's expected revenue is 229.72M.
What is TG Therapeutics Inc's price target?
Analysts forecast that TG Therapeutics Inc's price target is USD 49.00, with the highest forecast at USD 60.00 and the lowest forecast at USD 13.00.
How have TG Therapeutics IncTGTX's recent earnings per share performed?
The market expectation was USD 0.14, while TG Therapeutics IncTGTX's earnings per share (EPS) for the previous quarter was USD 0.17. EPS for the next quarter is expected at USD 0.34.
What is the analyst rating for TG Therapeutics Inc?
Based on the ratings of TG Therapeutics Inc's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.